AngiogenesisangiogenesisNCT00671242
Angiogenesis With Positron Emission Tomography (PET) Tracer Uptake
An observational study of Angiogenesis and Non-Small Cell Lung Cancer, run by Gunma University at 1 site in Japan.
Trial summary
Purpose: L-[3-18F]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for PET. We have conducted a clinicopathologic study to elucidate the correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in the patients with non-small cell lung cancer (NSCLC). Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Angiogenesis, Non-Small Cell Lung Cancer
- How many people
- Not given
- Where
- 1 siteJapan
- Study dates
- Start not givento not given
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patients who underwent a thoracotomy within 4 weeks after 18F-FMT PET and 18F-FDG PET study
- Histology is non-small cell lung cancer
Who cannot join
- Patient who received neoadjuvant chemotherapy or radiotherapy before surgery
- Patients who have insulin-dependent diabetes
Trial locations and contacts
1 site in 1 country.
Japan1 site
Gunma University Graduate School of Medicine
Showa-machi, Maebashi, Gunma, 371-8511
About this study
Official title: Correlation of Angiogenesis With 18F-FMT and 18F-FDG Uptake in Non-Small Cell Lung Cancer
Purpose: L-[3-18F]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for PET. We have conducted a clinicopathologic study to elucidate the correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in the patients with non-small cell lung cancer (NSCLC).
Method: Thirty-seven NSCLC patients were enrolled in this study, and a pair of PET study with 18F-FMT and 18F-FDG was performed. Uptake of PET tracers was evaluated with standardized uptake value. VEGF, CD31, CD34, LAT1 and Ki-67 labeling index of the resected tumors were analyzed by immunohistochemical staining, and correlated with the clinicopathologic variables and the uptake of PET tracers.
- Conditions
- Angiogenesis, Non-Small Cell Lung Cancer
- Keywords
- Fluorine-18-α-methyltyrosine,, Positron emission tomography,, Fluorine-18-fluorodeoxyglucose,, Lung cancer,, Angiogenesis, The median VEGF rate was 45% (range, 10-78%)., High expression was seen in 30 patients (81%, 30/37)., VEGF expression was statistically associated with progressively growing microvessel count.
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| I | L-[3-18F]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for PET. We have conducted a clinicopathologic study to elucidate the correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in the patients with non-small cell lung cancer | |
| Nuclear | Not described |
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 May 2008 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for AngiogenesisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
Sponsor and investigators
- Lead sponsor
- Gunma University
- Sponsor type
- University, hospital or other
- Collaborators
- J~pharma
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00671242
- Sponsor's protocol ID
- kkaira1970
- Acronym
- angiogenesis
- Status last verified
- Jan 2008
- First submitted
- 30 Apr 2008
- Last updated
- 5 May 2008
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Kaira K, Oriuchi N, Shimizu K, Ishikita T, Higuchi T, Imai H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T, Endo K, Mori M. Correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in non-small cell lung cancer. Cancer Sci. 2009 Apr;100(4):753-8. doi: 10.1111/j.1349-7006.2008.01077.x. Epub 2009 Jan 12.
PubMed 19141127
Study at a glance
From the registry record, last updated by the sponsor on 5 May 2008. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Correlation of Angiogenesis With 18F-FMT and 18F-FDG Uptake in Non-Small Cell Lung Cancer
- ClinicalTrials.gov ID
- NCT00671242
- Acronym / sponsor ID
- angiogenesis / kkaira1970
- Conditions
- Angiogenesis, Non-Small Cell Lung Cancer
- Keywords
- Fluorine-18-α-methyltyrosine,, Positron emission tomography,, Fluorine-18-fluorodeoxyglucose,, Lung cancer,, Angiogenesis, The median VEGF rate was 45% (range, 10-78%)., High expression was seen in 30 patients (81%, 30/37)., VEGF expression was statistically associated with progressively growing microvessel count.
- Study type
- Observational
- Recruitment status
- Completed
- Lead sponsor
- Gunma UniversityUniversity, hospital or other
- Collaborators
- J~pharma
- First posted
- 5 May 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Purpose: L-[3-18F]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for PET. We have conducted a clinicopathologic study to elucidate the correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in the patients with non-small cell lung cancer (NSCLC).
Method: Thirty-seven NSCLC patients were enrolled in this study, and a pair of PET study with 18F-FMT and 18F-FDG was performed. Uptake of PET tracers was evaluated with standardized uptake value. VEGF, CD31, CD34, LAT1 and Ki-67 labeling index of the resected tumors were analyzed by immunohistochemical staining, and correlated with the clinicopathologic variables and the uptake of PET tracers.
Study design
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| I | – | –L-[3-18F]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for PET. We have conducted a clinicopathologic study to elucidate the correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in the patients with non-small cell lung cancer |
| Nuclear | – | – |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (2 listed)
- Patients who underwent a thoracotomy within 4 weeks after 18F-FMT PET and 18F-FDG PET study
- Histology is non-small cell lung cancer
Key exclusion criteria (2 listed)
- Patient who received neoadjuvant chemotherapy or radiotherapy before surgery
- Patients who have insulin-dependent diabetes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 May 2008.
- Derived from this study: PubMed 19141127Kaira K, Oriuchi N, Shimizu K, Ishikita T, Higuchi T, Imai H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T, Endo K, Mori M. Correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in non-small cell lung cancer. Cancer Sci. 2009 Apr;100(4):753-8. doi: 10.1111/j.1349-7006.2008.01077.x. Epub 2009 Jan 12.
Related trials for Angiogenesis
Not yet recruitingPhase 2
Study of Suvemcitug Plus Chemotherapy in Advanced High-Grade Serous Ovarian Cancer
High-grade Serous Ovarian Cancer
Not yet recruitingPhase 2
First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal Mesothelioma
Peritoneal Mesothelioma, First-line Therapy
RecruitingPhase 1/2
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Locally Advanced / Metastatic Solid Tumors
RecruitingPhase 1/2
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
Kaposi Sarcoma
Active, not recruiting
Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents
Kidney Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Angiogenesis and Non-Small Cell Lung Cancer, run by Gunma University at 1 site in Japan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 May 2008. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00671242, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2008.